Research Analysts Offer Predictions for STOK FY2025 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Research analysts at Wedbush cut their FY2025 earnings per share estimates for Stoke Therapeutics in a research report issued to clients and investors on Wednesday, November 5th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of $0.12 for the year, down from their previous forecast of $0.35. Wedbush currently has a “Outperform” rating and a $32.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q4 2025 earnings at ($0.73) EPS, Q1 2026 earnings at ($0.71) EPS, Q2 2026 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.72) EPS, Q4 2026 earnings at ($0.73) EPS, FY2026 earnings at ($2.88) EPS, FY2027 earnings at ($3.20) EPS, FY2028 earnings at ($2.94) EPS and FY2029 earnings at $0.96 EPS.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%.The firm had revenue of $10.63 million during the quarter, compared to analysts’ expectations of $6.06 million.

STOK has been the topic of several other reports. BTIG Research restated a “buy” rating and set a $39.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. Chardan Capital reiterated a “buy” rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, August 13th. Canaccord Genuity Group boosted their price objective on Stoke Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday. Needham & Company LLC increased their target price on Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, October 10th. Finally, Jefferies Financial Group assumed coverage on Stoke Therapeutics in a research note on Friday, July 18th. They set a “buy” rating and a $30.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.00.

Stoke Therapeutics Price Performance

STOK opened at $22.47 on Friday. The firm has a market cap of $1.28 billion, a P/E ratio of 33.54 and a beta of 1.32. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $38.69. The company has a 50 day simple moving average of $26.40 and a two-hundred day simple moving average of $17.07.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Kennondale Capital Management LLC purchased a new position in shares of Stoke Therapeutics in the 1st quarter worth $280,000. Dauntless Investment Group LLC bought a new position in shares of Stoke Therapeutics in the 1st quarter valued at about $190,000. XTX Topco Ltd bought a new position in shares of Stoke Therapeutics in the 1st quarter valued at about $267,000. US Bancorp DE grew its position in Stoke Therapeutics by 9,743.9% in the first quarter. US Bancorp DE now owns 11,222 shares of the company’s stock worth $75,000 after acquiring an additional 11,108 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Stoke Therapeutics by 1.9% during the first quarter. Vanguard Group Inc. now owns 2,784,202 shares of the company’s stock worth $18,515,000 after acquiring an additional 53,004 shares during the last quarter.

Insider Buying and Selling

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 8th. The stock was sold at an average price of $30.00, for a total transaction of $750,000.00. Following the completion of the transaction, the director owned 49,124 shares in the company, valued at $1,473,720. This trade represents a 33.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Barry Ticho sold 5,931 shares of Stoke Therapeutics stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $25.72, for a total value of $152,545.32. Following the completion of the sale, the insider directly owned 7,195 shares in the company, valued at approximately $185,055.40. The trade was a 45.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 186,607 shares of company stock worth $4,224,210. Corporate insiders own 9.50% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.